

Jeremy P Harris

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1246090/publications.pdf>

Version: 2024-02-01

10
papers

42
citations

1936888

4
h-index

1872312

6
g-index

10
all docs

10
docs citations

10
times ranked

13
citing authors

#	ARTICLE	IF	CITATIONS
1	Adjuvant Therapy and Prognosticators of Survival in Head and Neck Mucosal Melanoma. Laryngoscope, 2022, 132, 584-592.	1.1	7
2	Bespoke circulating tumor DNA as a biomarker for treatment response in a refractory Merkel cell carcinoma patient. JAAD Case Reports, 2021, 18, 94-98.	0.4	7
3	Circulating tumor DNA as a predictive biomarker in Merkel cell carcinoma. Journal of the American Academy of Dermatology, 2022, , .	0.6	7
4	A Comprehensive Analysis of Treatment Management and Survival Outcomes in Nasopharyngeal Carcinoma. Otolaryngology - Head and Neck Surgery, 2020, 165, 019459982097324.	1.1	5
5	Impact of mental illness on end-of-life emergency department use in elderly patients with gastrointestinal malignancies. Cancer Medicine, 2021, 10, 2035-2044.	1.3	5
6	The clinical and financial cost of mental disorders among elderly patients with gastrointestinal malignancies. Cancer Medicine, 2020, 9, 8912-8922.	1.3	4
7	Longitudinal Analysis of Mental Disorder Burden Among Elderly Patients With Gastrointestinal Malignancies. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 163-171.	2.3	3
8	The role of chemotherapy plus immune checkpoint inhibitors in oncogenic driven non-small cell lung cancer: A University of California Lung Cancer Consortium retrospective study.. Journal of Clinical Oncology, 2021, 39, 9059-9059.	0.8	2
9	Detection of Recurrence After Thoracic Stereotactic Ablative Radiotherapy Using FDG-PET-CT. Clinical Lung Cancer, 2022, 23, 282-289.	1.1	1
10	Controversies in lung cancer: heterogeneity in treatment recommendations for stage III NSCLC according to disease burden and oncogenic driver alterations. Clinical Lung Cancer, 2022, , .	1.1	1